GAITHERSBURG, Md., Feb 21, 2002 /PRNewswire-FirstCall via COMTEX/ -- MedImmune,
Inc. (Nasdaq: MEDI) announced today the appointment of Elizabeth Wyatt to its
Board of Directors, replacing Lawrence Hoff, who is retiring.
"We are very pleased to welcome Elizabeth Wyatt to our Board of Directors," said
David. M. Mott, MedImmune's chief executive officer. "We have worked with
Elizabeth over the years and have come to respect her knowledge, integrity and
experience developed over her 20-year career at Merck. Having most recently
served as Merck's vice president, corporate licensing, Elizabeth brings
tremendous insight in the business development arena. Licensing and acquisitions
have always been an important element of MedImmune's growth strategies and we
look forward to Elizabeth's contributions in these areas and others.
Elizabeth Wyatt retired in December 2000 from Merck & Co. Inc. as vice
president, corporate licensing where she headed Merck's worldwide product and
technology acquisition activities. Prior to joining Merck in 1980, she had been
a consultant and an academic administrator, responsible for the Harvard Business
School's first formal marketing of its executive education programs. She
currently serves on the Boards of Directors of The Seabury Group LLC and certain
of its affiliates, and on the Board of Trustees of Randolph-Macon College. Wyatt
graduated with a bachelor of arts degree magna cum laude and Phi Beta Kappa from
Sweet Briar College. She earned a masters degree in education from Boston
University and a masters in business administration with honors from the Harvard
Commenting on Lawrence Hoff, Dr. Wayne T. Hockmeyer, MedImmune's founder and
chairman, stated: "Larry Hoff has been a valuable friend, mentor and counselor
to MedImmune for 11 years. His insight into the pharmaceutical industry has been
instrumental in MedImmune's successes. Every area of our business has benefited
from the knowledge gained during his illustrious 40- year career in the
pharmaceutical industry. We thank him for his outstanding contributions to
MedImmune, and for the professionalism and integrity with which he shared his
expertise during our long and fruitful relationship."
Hoff joined MedImmune's Board in April 1991, prior to the company's initial
public offering. In 1990, Hoff had retired as president and chief operating
officer of the Upjohn Company, where he began his career in 1950 as a
pharmaceutical sales representative. He rose steadily through the ranks at
Upjohn, where he was appointed vice president for Domestic Pharmaceutical
marketing in 1969; elected to UpJohn's Board of Directors in 1973; appointed
vice president and general manager of Domestic Pharmaceutical Operations in
1974; promoted to executive vice president in 1977; named president in 1984; and
selected as president and chief operating officer in 1987. Hoff was also a
leader in the pharmaceutical industry outside of Upjohn. In 1984, he was elected
to the Board of Directors of the Pharmaceuticals Manufacturers Association
("PMA"). In 1986, he was PMA's chairman-elect and in 1987 its chairman.
MedImmune is a leading biotechnology company focused on researching, developing
and commercializing products to prevent or treat infectious disease, autoimmune
disease and cancer. MedImmune currently markets three products, Synagis(R)
(palivizumab), Ethyol(R) (amifostine) and CytoGam(R) (cytomegalovirus immune
globulin intravenous (human)), and has 12 products in clinical testing.
MedImmune employs over 1,400 people, is headquartered in Gaithersburg, Maryland,
and has additional operations in Frederick, Maryland, as well as Pennsylvania,
California, the United Kingdom and the Netherlands. For more information on
MedImmune, visit the company's website at http://www.medimmune.com .
This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions. Actual
results could differ materially from those currently anticipated as a result of
a number of factors, including risks and uncertainties discussed in the
company's filings with the U.S. Securities and Exchange Commission. The company
is developing several products for potential future marketing. There can be no
assurance that such development efforts will succeed, that such products will
receive required regulatory clearance or that, even if such regulatory clearance
were received, such products would ultimately achieve commercial success.
MAKE YOUR OPINION COUNT - Click Here
SOURCE MedImmune, Inc.
CONTACT: Lori Weiman, Senior Director, Corporate Communications,
+1-301-527-4321, or Will Roberts, Manager, Investor Relations,
+1-301-527-4358, both of MedImmune, Inc.
Copyright (C) 2002 PR Newswire. All rights reserved.